Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/II Study of Trifluridine/Tipiracil (TAS102) in Combination With Nanoliposomal Irinotecan (NAL-IRI) in Advanced GI Cancers

Next Previous
X
Search
Trial Profile

A Phase I/II Study of Trifluridine/Tipiracil (TAS102) in Combination With Nanoliposomal Irinotecan (NAL-IRI) in Advanced GI Cancers

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 19 Jan 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Irinotecan (Primary) ; Tipiracil/trifluridine (Primary)
  • Indications Adenocarcinoma; Biliary cancer; Cholangiocarcinoma; Colorectal cancer; Gastrointestinal cancer; Oesophageal cancer; Pancreatic cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms OniLon

    • Most Recent Events

    • 12 Jan 2024 Planned End Date changed from 28 Nov 2024 to 28 Nov 2025.
    • 12 Jan 2024 Planned primary completion date changed from 28 Nov 2023 to 28 Nov 2024.
    • 06 Jun 2023 Results (n=22) presented at the 59th Annual Meeting of the American Society of Clinical Oncology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top